TARGETED THERAPY FOR
MELANOMA (BRAF/MEK)
BRAF/MEK inhibitor combinations produce response rates of 60-70% in BRAF V600-mutant melanoma -- among the highest in solid tumour targeted therapy. Responses often begin within days. The central limitation is resistance, which typically develops within 12-18 months.
Approved BRAF/MEK Inhibitor Combinations
| Combination | BRAF Inhibitor | MEK Inhibitor | Notes |
|---|---|---|---|
| Dabrafenib + Trametinib | Dabrafenib | Trametinib | First approved combination; established dual blockade rationale; approved metastatic and adjuvant stage III |
| Vemurafenib + Cobimetinib | Vemurafenib | Cobimetinib | Comparable clinical profile; choice often based on side effect preferences |
| Encorafenib + Binimetinib | Encorafenib | Binimetinib | Most recently approved; some data suggest lower pyrexia incidence than dabrafenib-based therapy |
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About BRAF/MEK Targeted Therapy for Your Melanoma?
CancerFax reviews your BRAF mutation status and treatment history to assess targeted therapy options and sequencing with immunotherapy.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.